Ethyl 2,2-difluoro-2-(2-oxo-2H-chromen-3-yl) acetate attenuates the malignant biological behaviors of non-small cell lung cancer via suppressing EGFR/PI3K/AKT/mTOR signaling pathway
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgae008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Liyi Zou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdo…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Guangdong Medical University.
Abstract (Originalsprache)
Objective
The goal of the study is to examine the impact on the malignant biological behaviors of non-small cell lung cancer (NSCLC) of a novel coumarin derivative, ethyl 2,2-difluoro-2-(2-oxo-2H-chromen-3-yl) acetate (C2F). It also aims to define its underlying mechanism.
Methods
NSCLC cell lines and xenograft nude mice model were conducted to explore the anti-NSCLC effects of C2F in vitro and in vivo. Then, network pharmacology analysis and molecular docking were applied to estimate the possible targets of C2F in NSCLC. Finally, the underlying mechanism of C2F against NSCLC cellular proliferation and tumor development was confirmed using inhibitors or activators of the PI3K/AKT signaling pathway.
Results
Our results showed that C2F was able to inhibit proliferation, migration, and invasion of NSCLC cell lines, induce cell cycle arrest and apoptosis in vitro, and prevent tumor growth in vivo. In addition, the estimated glomerular filtration rate and its downstream pathway (PI3K/AKT/mTOR) were found to be critical for the anti-NSCLC activity of C2F.
Conclusions
C2F inhibits malignant biological behaviors of NSCLC by suppressing EGFR/PI3K/AKT/mTOR signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong 523808, China.
- Department of Pharmacy, People's Hospital of Longhua District, Shenzhen, Guangdong 518109, China.
- Department of Physiology, College of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong 523808, China.
- Department of Pharmacy, Longgang District Maternity and Child Healthcare Hospital of Shenzhen City, Shenzhen, Guangdong 518172, China.
- Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
- Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR 999077, China.
ORCID-Profile: Zunnan Huang
Förderung
- Guangdong Medical University
Zitieren
APA
Zou, L., Li, X., Lin, J., Fang, X., Lin, J., Zhang, L., Zhang, Y., Liang, Y., Ren, J., Liu, Y., & Huang, Z. (2024). Ethyl 2,2-difluoro-2-(2-oxo-2H-chromen-3-yl) acetate attenuates the malignant biological behaviors of non-small cell lung cancer via suppressing EGFR/PI3K/AKT/mTOR signaling pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae008
Vancouver
Zou L, Li X, Lin J, Fang X, Lin J, Zhang L, et al. Ethyl 2,2-difluoro-2-(2-oxo-2H-chromen-3-yl) acetate attenuates the malignant biological behaviors of non-small cell lung cancer via suppressing EGFR/PI3K/AKT/mTOR signaling pathway. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae008
BibTeX
@article{Zou2024,
author = {Zou, Liyi and Li, Xiaodan and Lin, Jiansuo and Fang, Xuehong and Lin, Jie and Zhang, Lu and Zhang, Yan and Liang, Yanwen and Ren, Jianwei and Liu, Yi and Huang, Zunnan},
title = {Ethyl 2,2-difluoro-2-(2-oxo-2H-chromen-3-yl) acetate attenuates the malignant biological behaviors of non-small cell lung cancer via suppressing EGFR/PI3K/AKT/mTOR signaling pathway},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgae008}
}
EUVIMED